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CASE REPORT Open Access
Development of skin hypopigmentation in a
patient with metastatic papillary carcinoma
thyroid treated with Sorafenib
Syed Zubair Hussain1*, Ali Asghar1, Mubasher Ikram2 and Najmul Islam1
Abstract
Background: Sorafenib can be considered as the effective option of treatment in patients with metastatic
radioiodine refractory differentiated thyroid cancers. The cutaneous manifestations of Sorafenib include rash,
desquamation, hand foot skin reactions, pruritus, alopecia and erythema. We report the first case of
hypopigmentation related to sorafenib therapy.
Case presentation: We report the case of a middle aged gentleman with metastatic papillary carcinoma of thyroid
diagnosed in 2005. He was managed with total thyroidectomy, radioactive iodine and TSH suppressive therapy.
Despite receiving radioactive iodine 530 mci cumulative dose, patient had persistant disease with lung metastasis.
Therefore a TKI, sorafenib, was started. He developed hypopigmentation of the skin more prominent on face six
weeks after starting sorafenib treatment.He also developed diarrhea, desquamation of hands and feet, hair loss over
scalp, eye brows and moustache. Sorafenib treatment was discontinued. His diarrhea stopped in one week and
after four weeks his skin became normalized whereas he regained his hairs in six weeks.
Conclusion: To our knowledge, hypopigmentation in our patient appears to be the first reported of its kind in the
literature to date. Sorafenib is used in Renal cell carcinoma, Hepatcellular carcinoma and radioactive iodine
refractory thyroid carcinoma therefore it is very important to be aware of hypopigmentation as a potential side
effect for both physicians and patients.
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Background
Thyroid cancer is the most common and prevalent endo-
crine malignancy [1,2]. It accounts for about 95% of endo-
crine malignancies [2]. The most common type of thyroid
cancer is differentiated thyroid cancer (DTC) 95%, which
arise from the follicular cells of the thyroid and includes
papillary and follicular subtypes. Treatment of differen-
tiated thyroid cancer includes surgery, radioactive iodine
(I131) and TSH suppressive therapy. The prognosis in DTC
is usually good as these tumors are slowly progressive and
frequently curable with conventional treatment particularly
when detected at an earlier stage. About 10-22% of the pa-
tients develops distant metastatic disease and conventional
treatment is ineffective in about half of these patients [3].
In patients with distant metastasis refractory to conven-
tional treatment, expected survival declines rapidly [4,5].
Sorafenib is an multi-target tyrosine kinase inhibitor
that is given orally. It targets VEGFR 1-3 (vascular endo-
thelial growth factor receptors 1-3), BRAF (B-type Raf
kinase) and RET (rearranged during transfection) tyro-
sine kinase. It has an effect on proliferation of tumor
cells and angiogenesis [6]. Thyroid cancers are highly
vascular with over expression of VEGFR on their cells
[7]. This provide the rationale for use of sorafenib in
radioiodine refractory differentiated thyroid cancers.
The cutaneous manifestations of sorafenib include
rash, desquamation, hand foot skin reactions, pruritus,
alopecia and erythema [8]. We report the first case of
hypopigmentation related to sorafenib therapy.
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Case presentation
A 46 years male presented with on and off hemoptysis
and throat irritation for two years followed by voice
change for four months. Examination revealed hard nod-
ule of two cms on left lobe of thyroid gland with no
palpable lymphadenopathy and normal thyroid function
test. Laryngoscopy showed a mass in subglottic region
with mobile vocal cords and adequate airways. C.T scan
showed 4 x 3 cm mass in left lobe of thyroid extending
into left paralaryngeal space, prevertebral fascia on left
side with destruction of cricoid cartilage and enlarge-
ment of delphian node. Thyroid technetium scan re-
vealed cold nodule in left lobe which came out to be a
papillary carcinoma thyroid on fine needle aspiration cy-
tology (FNAC). He had total thyroidectomy with exci-
sion of paratracheal mass. Histopathology confirmed
papillary carcinoma thyroid. Stage was PT4, Nx, Mx
with no tumor identified in paratracheal tissue. Subse-
quently he received 100 mci of RAI131for remnant abla-
tion. Post ablative whole body scan (WBS) revealed no
distant metastasis. Six months later he had stimulated
thyroglobulin (sTg) of 2476 ng/ml with negative anti
thyroglobulin antibodies (Anti Tg) and his neck ultra-
sound revealed recurrent lesion of 1.9 x 1.4 cms with
metastatic lymph nodes in neck confirmed by subse-
quent CT Scan. He received RAI131 150 mci as the ini-
tial surgeon declined further surgery and post
therapeutic WBS revealed functioning thyroid tissue in
neck with no nodal or distant metastasis.
One year later his sTg was 2013 ng/ml with negative
Anti Tg and diagnostic WBS revealed residual disease in
thyroid bed with no nodal or distant metastasis. His CT
scan revealed heterogeneously enhancing thyroid mass
in left lobe measuring 3.6 x 3.6 cms with one centimeter
sized right supraclavicular and left level V lymph nodes.
He had excision of thyroid recurrence and left level VI
lymph nodes. Histopathology confirmed papillary Car-
cinoma thyroid with lymph node metastasis. He then re-
ceived further 100 mci of RAI131. Seven months later his
STg was 2328 ng/ml, anti Tg was negative and ultra-
sound revealed residual/recurrent disease in left lobe of
thyroid while his diagnostic whole body scan (WBS) was
negative. CT scan revealed residual thyroid disease with
multiple enlarged lymph nodes(left supraclavicular, left
level V, left level III) with metastatic nodules in both
lungs. Another dose of RAI131 120 mci given. Post thera-
peutic WBS revealed increased uptake over thyroid bed
and left cervical region but no uptake in the lung or
elsewhere in the body.
Despite receiving RAI131 530 mCi cumulative dose, pa-
tient had persistent disease with lung metastasis, there-
fore a TKI, sorafenib at a recommended dose of 400 my
twice daily was started. His unstimulated thyroglobulin
was 373 before starting sorafenib and dropped to 80.70
in 6 months. Initially after starting sorafenib he devel-
oped diarrhea which was initially whitish,watery and
later became solid. Its frequency was 6-8/day. Six weeks
after starting sorafenib he developed hypopigmentation
of skin of the whole body more marked on the face and
also had hair loss over scalp, eye brows and moustache
(Figure 1). He also experienced desquamation of hands
and feet that was non pruritic in nature and mainly on
sides of fingers, toes and at heels. Patient was not having
any coexisting disease and there was no history of any
other drug intake. He took sorafenib for 6 months. As
there was no other cause thought to be the culprit and pa-
tient was very much concerned with hypopigmentation
therefore Sorafenib was discontinued as patient preferred
it instead of reducing the dose. His diarrhea subsided
spontaneously a week later and his skin became norma-
lized spontaneously four weeks later (Figure 2).
Discussion
Sorafenib is a oral tyrosine kinase inhibitor. It is effective
in patients with advanced Hepatocellular carcinoma and
Renal cell carcinoma [9,10]. It is also effective in patients
with radioiodine refractory advanced thyroid cancers as
demonstrated in one phase III and three phase II clinical
trials [11-14]. These clinical trials with Sorafenib in
metastatic Differentiated thyroid cancers have shown ef-
ficacy in metastatic radioiodine refractory differentiated
thyroid cancers [11-14]. Scheider et al conducted a clin-
ical trial with Sorafenib in 31 radioactive iodine refrac-
tory thyroid cancer patients and found a median
progression free survival (PFS) of 18 months, median
overall survival (OS) of 34.5 months with a partial res-
ponse (PR) of 31% [11]. Gupta et al conducted a clinical
trial with Sorafenib in 30 radioactive iodine refractory
thyroid cancer patients and found a median progression
free survival (PFS) of 79 weeks, median overall survival
(OS) of 84 weeks with a partial response (PR) of 23%
[12]. Kloos et al conducted a clinical trial with Sorafenib
in 41 papillary thyroid cancer patients and found a
median progression free survival (PFS) of 15 months
with a partial response (PR) of 15% [13]. Brose MS et al
conducted a phase III DECISION trial with Sorafenib in
417 patients having radioiodine resistant advanced differ-
entiated thyroid cancer and found a PFS 10.8 months [14].
Sorafenib is associated with high frequency of dermato-
logical side effects which includes rash, desquamation,
hand foot skin reactions, pruritus, alopecia, subungual
splinter hemorrhages, alopecia, xerosis, scalp dysesthesia,
stomatitis and facial erythema [8,10,15-17]. Facial ery-
thematous eruptions is the most frequent cutaneous ad-
verse manifestation associated with sorafenib, its overall
incidence is 63% [15]. It usually appears 1 to 3 weeks after
starting treatment. Treatment of this side effect is symptom-
atic as it resolves spontaneously. Hand-foot skin reaction
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Figure 2 Photograph of same patient six weeks after discontinuation of sorafenib showing return of his normal skin colour with
regaining of hairs over scalp, eye brows and moustache.
Figure 1 Photograph of the patient while on sorafenib treatment showing hypopigmentation of face, hair loss over scalp, eye brows
and moustache.
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(HFSR) is the 2nd most frequent cutaneous adverse manifest-
ation associated with sorafenib, its overall incidence is 30% to
60% [10,15-17]. It usually appears after 2 to 3 weeks of treat-
ment [8]. Patients usually present with tingling or painful
sensations with a symmetric red areas on palms and soles
alongwith an intolerance to contact with cold objects. These
symptoms may affect walking. Frequently these patients
present with hyperkeratosis. Treatment is symptomatic with
or without dose reduction/interruption. Scalp dysesthesia is
found in 49% of the patients treated with sorafenib [15]. It
usually appears early within 3 weeks of starting sorafenib and
resolved spontaneously in few weeks. Alopecia with or with-
out body hair loss found in 26 to 44% of patients treated with
sorafenib [10,15,16]. It appears within 2 to 16 weeks after
starting treatment [15,16]. Hairs regrow spontaneously with
or without sorafenib discontinuation. Painless Subungual
splinter hemorrhages are reported in 70% sorafenib treated
patients [15]. They present as straight black or red lines
under the nails after 1 to 2 weeks of treatment and resolve
spontaneously [8,15]. Stomatitis is reported in 19 to 26% of
sorafenib treated patients [15,16]. It appears within fist eight
weeks of treatment and require either dose reduction or
transient drug interruption. Other cutaneous manifestations
of sorafenib includes Xerosis in 8 to 23% and Pruritus in 8 to
19% of sorafenib treated patients [10,15,17] and the treat-
ment is usually symptomatic.
To our knowledge, hypopigmentation in our patient ap-
pears to be the first reported of its kind in the literature to
date. It appeared six weeks after starting sorafenib. It was
generalized but more marked over face. Our patient took
sorafenib for alltogether 6 months. His skin became nor-
malized in four weeks after discontinuation of sorafenib.
The most important complication of hypopigmentation is
photosensitivity that can be treated with avoidance of sun
exposure and use of sun blocks.
Conclusion
Sorafenib is used in Renal cell carcinoma, Hepatcellular
carcinoma and radioactive iodine refractory thyroid car-
cinoma therefore it is very important to be aware of
hypopigmentation as a potential side effect for both
physicians and patients. Further studies are needed to
unveil the pathophysiology of this unique side-effect of
hypopigmentation with sorafenib in differentiated thy-
roid cancer patients.
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